following an abbreviated submission:
blinatumomab (Blincyto®) is accepted for use within NHSScotland.
Indication under review: As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukaemia which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.
SMC accepted blinatumomab for use in adults following a submission under the end of life and ultra-orphan process.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of blinatumomab. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
Download detailed advice365KB (PDF)
Medicine details
- Medicine name:
- blinatumomab (Blincyto)
- SMC ID:
- SMC2148
- Indication:
- as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation
- Pharmaceutical company
- Amgen Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 April 2019